Athenex Stock Price, News & Analysis (NASDAQ:ATNX)

$16.22 +0.19 (+1.19 %)
(As of 02/25/2018 04:00 PM ET)
Previous Close$16.22
Today's Range$15.73 - $16.22
52-Week Range$11.21 - $20.79
Volume158,476 shs
Average Volume424,131 shs
Market Capitalization$1.01 billion
P/E RatioN/A
Dividend YieldN/A
BetaN/A

About Athenex (NASDAQ:ATNX)

Athenex logoAthenex, Inc. is an oncology pharmaceutical company focused on the development and commercialization of therapies for cancer diseases and supportive therapies. The Company's technology platform is organized into three categories, including Oral Absorption Platform, Src Kinase Inhibitors and Symptom Therapeutics. The Company offers Oraxol, an oral formulation of paclitaxel; Orateacan, an oral formulation of Irinotecan; Oradoxel, an oral formulation of Docetaxel, and an oral formulation of Topotecan for the treatment of various types of cancers. Its Src Kinase Inhibitors include KX-01 (KX2-391) and KX-02 (KX2-361) oncology drug candidates. The Company's Symptom Therapeutics include CQ-01, which is used for the treatment of burn pruritus and scars; CQ-R1, which is used for the treatment of an irradiation-induced dermatitis, and an intranasal Granisetron used for the treatment of chemotherapy-induced nausea/vomiting.

Receive ATNX News and Ratings via Email

Sign-up to receive the latest news and ratings for ATNX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Bio Therapeutic Drugs
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:ATNX
CUSIPN/A
Phone716-427-2950

Debt

Debt-to-Equity RatioN/A
Current Ratio3.12%
Quick Ratio2.73%

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A

Profitability

Trailing EPSN/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A

Miscellaneous

Employees437
Outstanding Shares62,530,000

Athenex (NASDAQ:ATNX) Frequently Asked Questions

What is Athenex's stock symbol?

Athenex trades on the NASDAQ under the ticker symbol "ATNX."

Where is Athenex's stock going? Where will Athenex's stock price be in 2018?

5 brokerages have issued 12 month price targets for Athenex's stock. Their forecasts range from $20.00 to $36.00. On average, they expect Athenex's share price to reach $27.80 in the next twelve months. View Analyst Ratings for Athenex.

Who are some of Athenex's key competitors?

When did Athenex IPO?

(ATNX) raised $72 million in an IPO on Wednesday, June 14th 2017. The company issued 6,000,000 shares at $11.00-$13.00 per share. Credit Suisse, Deutsche, Bank Securities and J.P. Morgan served as the underwriters for the IPO and ICBC International was co-manager.

Who owns Athenex stock?

Athenex's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (1.74%), Greenleaf Trust (0.89%), Prince Street Capital Management LLC (0.28%), Geode Capital Management LLC (0.19%), Jaffetilchin Investment Partners LLC (0.19%) and Goldman Sachs Group Inc. (0.14%). Company insiders that own Athenex stock include Jinn Wu, Johnson Yiu Nam Lau, Manson Fok and Song-Yi Zhang. View Institutional Ownership Trends for Athenex.

Who sold Athenex stock? Who is selling Athenex stock?

Athenex's stock was sold by a variety of institutional investors in the last quarter, including Creative Planning and Bank of New York Mellon Corp. View Insider Buying and Selling for Athenex.

Who bought Athenex stock? Who is buying Athenex stock?

Athenex's stock was acquired by a variety of institutional investors in the last quarter, including BlackRock Inc., Prince Street Capital Management LLC, Jaffetilchin Investment Partners LLC, Greenleaf Trust, Alps Advisors Inc., Goldman Sachs Group Inc., Millennium Management LLC and Strs Ohio. Company insiders that have bought Athenex stock in the last two years include Jinn Wu, Johnson Yiu Nam Lau, Manson Fok and Song-Yi Zhang. View Insider Buying and Selling for Athenex.

How do I buy Athenex stock?

Shares of Athenex can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Athenex's stock price today?

One share of Athenex stock can currently be purchased for approximately $16.22.

How big of a company is Athenex?

Athenex has a market capitalization of $1.01 billion. Athenex employs 437 workers across the globe.

How can I contact Athenex?

Athenex's mailing address is 1001 Main Street Suite 600, Buffalo NY, 14203. The company can be reached via phone at 716-427-2950.


MarketBeat Community Rating for Athenex (ATNX)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  70 (Vote Outperform)
Underperform Votes:  74 (Vote Underperform)
Total Votes:  144
MarketBeat's community ratings are surveys of what our community members think about Athenex and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Athenex (NASDAQ:ATNX) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.802.802.803.00
Ratings Breakdown: 0 Sell Rating(s)
1 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $27.80$27.80$27.64$20.00
Price Target Upside: 91.99% upside91.99% upside62.21% upside8.58% upside

Athenex (NASDAQ:ATNX) Consensus Price Target History

Price Target History for Athenex (NASDAQ:ATNX)

Athenex (NASDAQ:ATNX) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
1/24/2018JPMorgan Chase & Co.Boost Price TargetNeutral -> Neutral$22.20 -> $23.00LowView Rating Details
1/17/2018Deutsche BankSet Price TargetBuy$20.00HighView Rating Details
9/19/2017LaidlawInitiated CoverageBuy$36.00MediumView Rating Details
9/18/2017Credit Suisse GroupInitiated CoverageOutperform -> Outperform$25.00LowView Rating Details
9/14/2017Royal Bank of CanadaInitiated CoverageOutperform -> Outperform$35.00HighView Rating Details
(Data available from 2/25/2016 forward)

Earnings

Athenex (NASDAQ:ATNX) Earnings History and Estimates Chart

Earnings by Quarter for Athenex (NASDAQ:ATNX)

Athenex (NASDAQ ATNX) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/9/2017Q3 2017($0.30)$13.99 millionViewN/AView Earnings Details
8/14/2017Q2 2017($0.88)$4.60 millionViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Athenex (NASDAQ:ATNX) Earnings Estimates

Current Year EPS Consensus Estimate: $-2.3 EPS
Next Year EPS Consensus Estimate: $-1.76 EPS

Dividends

Dividend History for Athenex (NASDAQ:ATNX)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Athenex (NASDAQ ATNX) Insider Trading and Institutional Ownership History

Institutional Ownership Percentage: 4.03%
Insider Trades by Quarter for Athenex (NASDAQ:ATNX)
Insider Trades by Quarter for Athenex (NASDAQ:ATNX)

Athenex (NASDAQ ATNX) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
2/9/2018Jinn WuDirectorBuy10,000$13.64$136,400.00249,208View SEC Filing  
2/8/2018Johnson Yiu Nam LauCEOBuy20,000$14.40$288,000.002,767,922View SEC Filing  
2/7/2018Manson FokDirectorBuy30,000$14.31$429,300.001,799,609View SEC Filing  
6/19/2017Johnson Yiu Nam LauCEOBuy25,200$11.00$277,200.002,722,722View SEC Filing  
6/19/2017Song-Yi ZhangDirectorBuy328,637$11.00$3,615,007.004,000View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Athenex (NASDAQ ATNX) News Headlines

Source:
DateHeadline
Tax breaks approved for Athenex and TomricTax breaks approved for Athenex and Tomric
finance.yahoo.com - February 23 at 4:51 PM
Athenex Inc (ATNX) Receives Consensus Recommendation of "Buy" from AnalystsAthenex Inc (ATNX) Receives Consensus Recommendation of "Buy" from Analysts
www.americanbankingnews.com - February 23 at 3:30 AM
Athenex to Present at 2018 RBC Capital Markets Healthcare ConferenceAthenex to Present at 2018 RBC Capital Markets Healthcare Conference
finance.yahoo.com - February 16 at 9:11 AM
Athenex (ATNX) Reports Early Completion of Patients Enrollment for Two Phase III Clinical Studies of KX2-391 Ointment for Actinic KeratosisAthenex (ATNX) Reports Early Completion of Patients Enrollment for Two Phase III Clinical Studies of KX2-391 Ointment for Actinic Keratosis
www.streetinsider.com - February 15 at 4:31 PM
Athenex Meets Enrollment Target for Oraxol Phase III Clinical Trial in Metastatic Breast CancerAthenex Meets Enrollment Target for Oraxol Phase III Clinical Trial in Metastatic Breast Cancer
finance.yahoo.com - February 15 at 8:49 AM
Athenex Announces Early Completion of Patients Enrollment for Two Phase III Clinical Studies of KX2-391 Ointment for Actinic KeratosisAthenex Announces Early Completion of Patients Enrollment for Two Phase III Clinical Studies of KX2-391 Ointment for Actinic Keratosis
finance.yahoo.com - February 14 at 9:06 AM
Athenex Announces Recent Product Launches in 503B and Specialty Injectables Business UnitsAthenex Announces Recent Product Launches in 503B and Specialty Injectables Business Units
finance.yahoo.com - February 13 at 9:05 AM
Athenex Inc (ATNX) CEO and Chairman of the Board Johnson Yiu Nam Lau Bought $288,000 of SharesAthenex Inc (ATNX) CEO and Chairman of the Board Johnson Yiu Nam Lau Bought $288,000 of Shares
finance.yahoo.com - February 10 at 9:00 AM
Insider Buying: Athenex Inc (ATNX) Director Buys 10,000 Shares of StockInsider Buying: Athenex Inc (ATNX) Director Buys 10,000 Shares of Stock
www.americanbankingnews.com - February 9 at 6:32 PM
Johnson Yiu Nam Lau Purchases 20,000 Shares of Athenex Inc (ATNX) StockJohnson Yiu Nam Lau Purchases 20,000 Shares of Athenex Inc (ATNX) Stock
www.americanbankingnews.com - February 9 at 6:20 PM
Insider Buying: Athenex Inc (ATNX) Director Acquires 30,000 Shares of StockInsider Buying: Athenex Inc (ATNX) Director Acquires 30,000 Shares of Stock
www.americanbankingnews.com - February 9 at 6:20 PM
Athenex Inc (ATNX) Receives Consensus Rating of "Buy" from BrokeragesAthenex Inc (ATNX) Receives Consensus Rating of "Buy" from Brokerages
www.americanbankingnews.com - January 29 at 3:32 AM
Athenex (ATNX) Given New $23.00 Price Target at JPMorgan Chase & Co.Athenex (ATNX) Given New $23.00 Price Target at JPMorgan Chase & Co.
www.americanbankingnews.com - January 28 at 2:22 PM
Athenex, Inc. Announces Pricing of Offering of Common StockAthenex, Inc. Announces Pricing of Offering of Common Stock
finance.yahoo.com - January 25 at 9:05 AM
Wired News – Athenex Announced Positive Results of Phase-I Clinical Trial of Oraxol and CYRAMZA(R) Combination Treatment in Gastric CancerWired News – Athenex Announced Positive Results of Phase-I Clinical Trial of Oraxol and CYRAMZA(R) Combination Treatment in Gastric Cancer
finance.yahoo.com - January 24 at 9:31 AM
Athenex (ATNX) Announces Proposed 4.3M Common Share OfferingAthenex (ATNX) Announces Proposed 4.3M Common Share Offering
www.streetinsider.com - January 22 at 5:47 PM
Athenex (ATNX) & Its Peers Head to Head SurveyAthenex (ATNX) & Its Peers Head to Head Survey
www.americanbankingnews.com - January 17 at 3:12 AM
Athenex (ATNX) Reports Positive Feedback from FDA on Design of Phase III Clinical Trial for OraxolAthenex (ATNX) Reports Positive Feedback from FDA on Design of Phase III Clinical Trial for Oraxol
www.streetinsider.com - January 16 at 9:05 AM
Athenex Receives Positive Feedback from FDA on the Design of Phase III Clinical Trial for OraxolAthenex Receives Positive Feedback from FDA on the Design of Phase III Clinical Trial for Oraxol
finance.yahoo.com - January 16 at 9:05 AM
Athenex signs general contractor for 320,000-square-foot factory in DunkirkAthenex signs general contractor for 320,000-square-foot factory in Dunkirk
finance.yahoo.com - January 9 at 5:59 PM
Investors Are Undervaluing Athenex Inc (NASDAQ:ATNX) By 35.71%, Here Is My Intrinsic Value CalculationInvestors Are Undervaluing Athenex Inc (NASDAQ:ATNX) By 35.71%, Here Is My Intrinsic Value Calculation
finance.yahoo.com - January 9 at 9:04 AM
Athenex (ATNX) Granted Allowance from Chinese FDA of Investigational New Drug Application of Oraxol to Begin Clinical TrialsAthenex (ATNX) Granted Allowance from Chinese FDA of Investigational New Drug Application of Oraxol to Begin Clinical Trials
www.streetinsider.com - January 8 at 5:57 PM
Athenex Announces Chinese FDA Allowance of Investigational New Drug Application of Oraxol to Begin Clinical TrialsAthenex Announces Chinese FDA Allowance of Investigational New Drug Application of Oraxol to Begin Clinical Trials
finance.yahoo.com - January 8 at 12:05 PM
Athenex Inc (ATNX) Given Consensus Recommendation of "Buy" by BrokeragesAthenex Inc (ATNX) Given Consensus Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - January 4 at 7:58 AM
 Athenex Inc (ATNX) Given $25.73 Average Target Price by Brokerages Athenex Inc (ATNX) Given $25.73 Average Target Price by Brokerages
www.americanbankingnews.com - January 3 at 3:34 AM
What Should You Know About Athenex Inc’s (NASDAQ:ATNX) Earnings Outlook?What Should You Know About Athenex Inc’s (NASDAQ:ATNX) Earnings Outlook?
finance.yahoo.com - January 1 at 5:41 PM
 Athenex Inc (ATNX) Receives Average Rating of "Buy" from Brokerages Athenex Inc (ATNX) Receives Average Rating of "Buy" from Brokerages
www.americanbankingnews.com - December 28 at 5:34 PM
Athenex (ATNX) Oraxol Granted Promising Innovative Medicine Designation in UKAthenex (ATNX) Oraxol Granted Promising Innovative Medicine Designation in UK
www.streetinsider.com - December 28 at 5:13 PM
Athenex Receives Promising Innovative Medicine Designation from the United Kingdom MHRA for Oraxol, An Innovative Oral Form of PaclitaxelAthenex Receives Promising Innovative Medicine Designation from the United Kingdom MHRA for Oraxol, An Innovative Oral Form of Paclitaxel
finance.yahoo.com - December 28 at 5:13 PM
 Athenex Inc (ATNX) Given $25.73 Consensus Target Price by Brokerages Athenex Inc (ATNX) Given $25.73 Consensus Target Price by Brokerages
www.americanbankingnews.com - December 24 at 9:53 PM
Critical Review: Athenex (ATNX) & Its PeersCritical Review: Athenex (ATNX) & Its Peers
www.americanbankingnews.com - December 23 at 11:22 PM
Athenex Inc (NASDAQ:ATNX): Should The Recent Earnings Drop Worry You?Athenex Inc (NASDAQ:ATNX): Should The Recent Earnings Drop Worry You?
finance.yahoo.com - December 23 at 6:43 AM
Zacks: Athenex Inc (ATNX) Receives Consensus Rating of "Buy" from AnalystsZacks: Athenex Inc (ATNX) Receives Consensus Rating of "Buy" from Analysts
www.americanbankingnews.com - December 21 at 5:40 PM
Athenex (ATNX) and Melinta Therapeutics (MLNT) Critical SurveyAthenex (ATNX) and Melinta Therapeutics (MLNT) Critical Survey
www.americanbankingnews.com - December 19 at 7:10 PM
Athenex, Inc. Added to Nasdaq Biotechnology IndexAthenex, Inc. Added to Nasdaq Biotechnology Index
finance.yahoo.com - December 18 at 9:08 AM
Zacks: Athenex Inc (ATNX) Given Consensus Rating of "Buy" by AnalystsZacks: Athenex Inc (ATNX) Given Consensus Rating of "Buy" by Analysts
www.americanbankingnews.com - December 16 at 1:52 AM
Athenex Announces Initiation of an Oral Eribulin Investigational New Drug Development Program for Oncology IndicationsAthenex Announces Initiation of an Oral Eribulin Investigational New Drug Development Program for Oncology Indications
finance.yahoo.com - December 15 at 9:17 AM
Zacks: Athenex Inc (ATNX) Given $25.73 Consensus Price Target by AnalystsZacks: Athenex Inc (ATNX) Given $25.73 Consensus Price Target by Analysts
www.americanbankingnews.com - December 12 at 7:34 PM
Almirall and Athenex announce strategic partnership for the treatment of actinic keratosisAlmirall and Athenex announce strategic partnership for the treatment of actinic keratosis
finance.yahoo.com - December 11 at 6:01 PM
ETFs with exposure to Athenex, Inc. : December 11, 2017ETFs with exposure to Athenex, Inc. : December 11, 2017
finance.yahoo.com - December 11 at 6:01 PM
Zacks: Athenex Inc (ATNX) Given Consensus Recommendation of "Buy" by AnalystsZacks: Athenex Inc (ATNX) Given Consensus Recommendation of "Buy" by Analysts
www.americanbankingnews.com - December 5 at 1:36 AM
Athenex Incs Lock-Up Period Set To Expire  on December 11th (NASDAQ:ATNX)Athenex Inc's Lock-Up Period Set To Expire on December 11th (NASDAQ:ATNX)
www.americanbankingnews.com - December 4 at 1:52 AM
Athenex (ATNX) Reports Planned Retirement of CFO Nick RiehleAthenex (ATNX) Reports Planned Retirement of CFO Nick Riehle
www.streetinsider.com - December 1 at 4:22 PM
Athenex, Inc. breached its 50 day moving average in a Bearish Manner : ATNX-US : December 1, 2017Athenex, Inc. breached its 50 day moving average in a Bearish Manner : ATNX-US : December 1, 2017
finance.yahoo.com - December 1 at 4:22 PM
Athenex Announces Planned Retirement of Chief Financial Officer Nick RiehleAthenex Announces Planned Retirement of Chief Financial Officer Nick Riehle
finance.yahoo.com - December 1 at 4:22 PM
ETFs with exposure to Athenex, Inc. : November 30, 2017ETFs with exposure to Athenex, Inc. : November 30, 2017
finance.yahoo.com - November 30 at 5:46 PM
Athenex (ATNX) Announces Acceptance of Phase II Data of KX2-391 for Treatment of Actinic Keratosis for PresentationAthenex (ATNX) Announces Acceptance of Phase II Data of KX2-391 for Treatment of Actinic Keratosis for Presentation
www.streetinsider.com - November 29 at 8:56 AM
Athenex, Inc. :ATNX-US: Earnings Analysis: Q3, 2017 By the Numbers : November 29, 2017Athenex, Inc. :ATNX-US: Earnings Analysis: Q3, 2017 By the Numbers : November 29, 2017
finance.yahoo.com - November 29 at 8:56 AM
Athenex Announces Acceptance of Phase II Data of KX2-391 for the Treatment of Actinic Keratosis for Presentation at the American Academy of Dermatology Meeting on February 17, 2018Athenex Announces Acceptance of Phase II Data of KX2-391 for the Treatment of Actinic Keratosis for Presentation at the American Academy of Dermatology Meeting on February 17, 2018
finance.yahoo.com - November 28 at 5:47 PM
Head-To-Head Review: Achillion Pharmaceuticals (ACHN) versus Athenex (ATNX)Head-To-Head Review: Achillion Pharmaceuticals (ACHN) versus Athenex (ATNX)
www.americanbankingnews.com - November 24 at 1:42 PM

SEC Filings

Athenex (NASDAQ:ATNX) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Athenex (NASDAQ:ATNX) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Athenex (NASDAQ ATNX) Stock Chart for Sunday, February, 25, 2018

Loading chart…

This page was last updated on 2/25/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.